We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Radiation After Lumpectomy Better for Most Older, Early-Stage Breast Cancer Patients

By MedImaging International staff writers
Posted on 23 Aug 2012
For the majority of older, early-stage breast cancer patients, radiation therapy following breast-conserving surgery may help prevent the need for a later mastectomy.

The findings, published August 15, 2012, in the journal Cancer, are contrary to current US treatment guidelines, which recommend that older women with early stage, estrogen-positive disease be treated with lumpectomy followed by estrogen blocker therapy alone--and skip altogether radiation therapy postsurgery. The potential benefit of radiation in this patient population has been the focus of much research over the past 10 years, according to Benjamin Smith, MD, assistant professor in the department of radiation therapy at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), and the study’s corresponding author.

In 2004, a major study revealed that women who received tamoxifen alone, compared to tamoxifen and six weeks of radiation, had a slightly higher incidence of breast cancer recurrence. Nevertheless, there was no difference in mastectomy rates or survival between the two cohorts, according to Dr. Smith. Based on these findings, the US National Comprehensive Cancer Network (NCCN; Fort Washington, PA, USA), adjusted its treatment guidelines, and radiation therapy following lumpectomy was no longer recommended. Dr. Smith then followed up this guideline-changing research with a population-based study, confirming the earlier findings with respect to breast cancer recurrence.

“The motivation for this new research was to do a similarly designed study with longer term follow up,” stated Dr. Smith. “We wanted to do a 10-year update, focusing specifically on the mastectomy question. The fundamental reason it was determined that women didn’t need radiation was because the additional therapy did not change mastectomy rates.”

For the population-based study, Dr. Smith and his colleagues derived a cohort of US Medicare patients from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry who would have been eligible for the 2004 study. The researchers identified 7,403 patients ages 70-79 treated with a lumpectomy for early-stage estrogen-positive breast cancer. All were diagnosed between 1992 and 2002, with follow-up through 2007. Of the 7,403 women, 88% received radiation after their lumpectomy.

Within 10 years of their treatment, 6.3% of the women who did not receive radiation therapy had a mastectomy, likely because of a breast cancer recurrence, according to Dr. Smith, compared to 3.2% who had the further treatment. In patients with high-grade tumors, irrespective of other factors such as age and/or tumor characteristics, radiation appeared to be very beneficial. The researchers also discovered a subset of women for whom radiation did not benefit, and therefore could be omitted from care regimen: those 75-79 years of age who had their lymph nodes assessed and did not have high-grade tumors.

“I think the national guidelines, while well intended and important, may gloss over the certain nuances needed for making critical decisions with patients,” concluded Dr. Smith. “Our study may shed additional light on some of those nuances and provides data that physicians can use when talking to their patients about whether to go forward with radiation. Personally, having this data point, together with the previous findings, gives me the confidence to not routinely recommend radiation in women age 75 and over with non-high grade tumors.”

Related Links:

University of Texas MD Anderson Cancer Center
US National Comprehensive Cancer Network



Post-Processing Imaging System
DynaCAD Prostate
Biopsy Software
Affirm® Contrast
Breast Localization System
MAMMOREP LOOP
X-ray Diagnostic System
FDX Visionary-A

Channels

Nuclear Medicine

view channel
Image: LHSCRI scientist Dr. Glenn Bauman stands in front of the PET scanner (Photo courtesy of LHSCRI)

New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer

Detecting recurrent prostate cancer remains one of the most difficult challenges in oncology, as standard imaging methods such as bone scans and CT scans often fail to accurately locate small or early-stage tumors.... Read more

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.